caa a22 4500 606187219 CHVBK 20210128100839.0 cr unu---uuuuu 210128e20151101xx s 000 0 eng 10.1007/s00405-014-3360-4 doi (NATIONALLICENCE)springer-10.1007/s00405-014-3360-4 Corticosteroid treatment of idiopathic sudden sensorineural hearing loss: analysis of an RCT and material drawn from the Swedish national database [Elektronische Daten] [Elisabeth Hultcrantz, Ramesh Nosrati-Zarenoe] A randomized placebo-controlled study has demonstrated no effect of prednisolone in customary dosage on idiopathic sudden sensorineural hearing loss (ISSNHL). The aim of the present paper is to analyse a larger patient group by meta-analysis of data from the RCT together with a corresponding material drawn from the Swedish national database for ISSNHL. Data from 192 patients, 18-80years with ISSNHL, were available. All had an acute hearing loss of at least 30dB measured as PTA in the three most affected contiguous frequencies. All patients had been enrolled within one week after onset and evaluated by audiograms after 3 months. 45/99 (RCT) and 54/99 (the database) had been treated with prednisolone in tapering doses from 60mg daily and 42/93 with placebo (RCT) or 51/93 with no treatment (the database). Primary outcome was the mean hearing improvement on day 90 for the different groups. A mean difference of >10dB improvement was required to demonstrate a treatment effect for prednisolone compared to placebo/no treatment. No significant difference was seen between the prednisolone group and placebo/no treatment (p=0.06). Total recovery was 38% in prednisolone group, 40% in the placebo and 14% in the no treatment group. Vertigo at the onset of hearing loss and age at onset had an equal negative prognostic value in all groups and signs of inflammation had a positive effect. Prednisolone in customary dosage does not influence recovery after ISSNHL. Springer-Verlag Berlin Heidelberg, 2014 Idiopathic sudden sensorineural hearing loss nationallicence Sudden deafness nationallicence Prednisolone nationallicence Effect of treatment nationallicence Placebo nationallicence Vertigo nationallicence Hultcrantz Elisabeth Division of Otorhinolaryngology, Department of Clinical and Experimental Medicine, Medical Faculty, Linköping University, Linköping, Sweden aut Nosrati-Zarenoe Ramesh Division of Otorhinolaryngology, Department of Clinical and Experimental Medicine, Medical Faculty, Linköping University, Linköping, Sweden aut European Archives of Oto-Rhino-Laryngology Springer Berlin Heidelberg 272/11(2015-11-01), 3169-3175 0937-4477 272:11<3169 2015 272 405 https://doi.org/10.1007/s00405-014-3360-4 text/html Onlinezugriff via DOI BK010053 XK010053 XK010000 Metadata rights reserved Springer special CC-BY-NC licence nationallicence 1 research-article jats NATIONALLICENCE NATIONALLICENCE NL-springer NATIONALLICENCE 856 40 https://doi.org/10.1007/s00405-014-3360-4 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Hultcrantz Elisabeth Division of Otorhinolaryngology, Department of Clinical and Experimental Medicine, Medical Faculty, Linköping University, Linköping, Sweden aut NATIONALLICENCE 700 1- Nosrati-Zarenoe Ramesh Division of Otorhinolaryngology, Department of Clinical and Experimental Medicine, Medical Faculty, Linköping University, Linköping, Sweden aut NATIONALLICENCE 773 0- European Archives of Oto-Rhino-Laryngology Springer Berlin Heidelberg 272/11(2015-11-01), 3169-3175 0937-4477 272:11<3169 2015 272 405